July 24th 2025
The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.
9th Annual School of Nursing Oncology™
August 9, 2025
Register Now!
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
PER's Satellite Symposia at MHS
August 1-2, 2025
Register Now!
A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and AD...
September 6, 2025
Register Now!
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
11th Annual School of Gastrointestinal Oncology® (SOGO®)
April 11, 2026
Register Now!
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Patients With ESCC Derive Survival Benefit With Tiragolumab Plus Atezolizumab and Chemotherapy
January 20th 2024Patients with esophageal squamous cell carcinoma obtained significant survival improvements when treated with tiragolumab plus atezolizumab and chemotherapy compared with chemotherapy alone.
Adding Nivolumab to Chemo Increases OS, PFS in Previously Untreated Advanced GI Cancers
January 19th 2024Overall survival and progression-free survival improves with nivolumab plus chemotherapy compared with chemotherapy alone in the overall population and in patients with a PD-L1 CPS of 5 or greater.
First-Line Pembrolizumab Shows A Trend Towards Overall Survival in MSI-D/dMMR mCRC
December 2nd 2023The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.
New Companion Diagnostic Is Approved to Aid In Gastric Cancer Decision Making
November 15th 2023The PD-L1 IHC 22C3 pharmDx diagnostic tool will help identify patients with gastric or gastroesophageal junction adenocarcinoma whose disease expresses PD-L1 and who are thereby eligible for pembrolizumab.
GVAX Cancer Vaccine Generates Responses in Patients With Pancreatic Adenocarcinoma
August 16th 2023The median disease-free survival with GVAX vaccine plus low-dose cyclophosphamide; GVAX plus cyclophosphamide and nivolumab; and GVAX plus cyclophosphamide, nivolumab, and urelumab, was 13.90 months, 26.1 months, and 31.6 months, respectively.
Trastuzumab Deruxtecan Elicits Durable Response in HER2+ Gastric/GEJ Cancer
July 19th 2023Trastuzumab deruxtecan elicited a confirmed objective response rate of 42% in patients with HER2-positive gastric or gastroesophageal junction cancer, according to findings from the phase 2 DESTINY-Gastric02 trial.